Ascentage Pharma Group International ADR
AAPGHealthcare·Biotechnology·China·Small·NASD·Nov 13 • 4:19 AM ET
14.82-0.20 (-1.33%)
2026-11-13 12:50 CET
Market cap
$1.38B
Revenue, TTM
91.82 USD m
Net income, TTM
-210.51 USD m
Free cash flow, TTM
-202.81 USD m
EPS diluted, TTM
-2.26
Price
AAPG against its 20, 50 and 200-day averagesPatternshover a marker to name it
57.0% under the 52-week high of 34.50 on 3 Nov 2025. 52-week low 13.46 on 2 Nov 2026. Last 15 sessions, 18.1% high to low
Volume 9.86× normal · the line is the 50-bar volume average
Setup. RS line 1
CANSLIM 1 of 6 — fails: 52-Week High/Low: 0-10% below High; Performance: Year +50%; Institutional Ownership: Over 50%; Average Volume: Over 200K — not on the tape: EPS Growth Qtr Over Qtr: High (>25%)
VCP 2 of 6 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High; Relative Volume: Under 1
Minervini 0 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High; Performance: Year +50%
Zanger 1 of 5 — fails: RSI (14): Not Oversold (>50); Performance: Week +10%; 20-Day High/Low: 0-5% below High; 200-Day Simple Moving Average: Price above SMA200
Leaders 0 of 5 — fails: 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%; Average Volume: Over 500K; 52-Week High/Low: 0-10% below High
Breakout 1 of 4 — fails: 52-Week High/Low: New High; 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200
Growth 1 of 4 — fails: EPS Growth Next Year: High (>25%); Return on Equity: Over +15% — not on the tape: EPS Growth Qtr Over Qtr: High (>25%)
Quality 1 of 5 — fails: Return on Equity: Over +15%; Net Profit Margin: High (>20%); Debt/Equity: Low (<0.1) — not on the tape: P/E: Under 25
Value 0 of 4 — fails: P/B: Under 2; Return on Equity: Over +15%; Debt/Equity: Low (<0.1) — not on the tape: P/E: Under 15
Income 0 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%; Payout Ratio: Low (<20%); P/E: Under 25
Small Cap 0 of 4 — fails: Average Volume: Over 500K; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50% — not on the tape: Float: Under 100M
Accumulation 0 of 4 — fails: Institutional Ownership: Over 30%; Institutional Transactions: Over +10%; 200-Day Simple Moving Average: Price above SMA200; Performance: Year Up
Relative Strength 0 of 3 — fails: Performance: Year +100%; 200-Day Simple Moving Average: Price above SMA200; Average Volume: Over 500K
Profile
AAPG52-week range, 6% of the way up
13.4634.50
Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.
| Employees | 767 |
|---|---|
| IPO | Jan 27, 2025 |
| Beta | 0.19 |
| ATR, 14d | 0.62 |
| Rel volume | 9.86 |
| Inst own | 0.02% |
Snapshot
6 groupsValuation
| Index | - |
|---|---|
| Market Cap | $1.38B |
| Enterprise Value | 1.41B |
| Income | -210.51M |
| Sales | 91.82M |
| Book / share | 0.88 |
| Cash / share | 2.99 |
| Dividend Est. | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Dividend Gr. 3/5Y | - - |
| Payout | - |
| Employees | 767 |
| IPO | Jan 27, 2025 |
Ratios
| Price / earnings | - |
|---|---|
| Forward price / earnings | - |
| Price / earnings / growth | - |
| Price / sales | 15.06 |
| Price / book | 16.80 |
| Price / cash | 4.95 |
| Price / free cash flow | - |
| Value / cash profit | - |
| Value / sales | 15.39 |
| Quick Ratio | 1.18 |
| Current Ratio | 1.22 |
| Debt / equity | 3.76 |
| Long-term debt / equity | 1.11 |
| Options and short | No / Yes |
Earnings
| Earnings / share | -2.26 |
|---|---|
| Earnings next year | -0.46 |
| Earnings next quarter | -0.36 |
| Earnings this year | 75.27% |
| Earnings next year | 7.33% |
| Earnings growth, 5 years | 48.61% |
| Past earnings growth | 0.80% -1.32% |
| Past sales growth | 36.88% 113.42% |
| Earnings vs last year | -12.46% |
| Sales vs last year | 69.80% |
| Earnings vs last quarter | - |
| Sales vs last quarter | - |
| Earnings | Aug 18 AMC |
| Surprise | -490.95% -16.37% |
Ownership
| Insiders own | - |
|---|---|
| Insider trades | - |
| Institutions own | 0.02% |
| Institution trades | 4.53% |
| Return on assets | -46.64% |
| Return on equity | -240.66% |
| Return on capital | -121.48% |
| Gross Margin | 83.18% |
| Operating margin | -220.00% |
| Profit Margin | -229.27% |
| 20-day average | -1.52% |
| 50-day average | -3.74% |
| 200-day average | -24.73% |
Technical
| Shares out | 52.23M |
|---|---|
| Shares floating | - |
| Short / float | - |
| Short ratio | 1.25 |
| Short interest | 0.01M |
| 52-week high | 34.50 -57.0% |
| 52-week low | 13.46 +10.1% |
| Volatility | 2.54% 3.14% |
| Average range | 0.62 |
| Strength index | 46.98 |
| Market sensitivity | 0.19 |
| Relative volume | 9.86 |
| Avg Volume | 7.30K |
| Volume | 3,596 |
Performance
| Perf Week | -3.95% |
|---|---|
| Perf Month | 0.88% |
| Perf Quarter | -18.57% |
| Perf Half Y | -24.00% |
| Perf YTD | -43.52% |
| Perf Year | -55.99% |
| Perf 3Y | - |
| Perf 5Y | - |
| Perf 10Y | - |
| Recommendation | 1.00 |
| Target Price | 43.56 |
| Prev Close | 15.02 |
| Price | 14.82 |
| Change % | -1.33% |
Analyst ratings
latest 10 of 11| Date | Action | Analyst | Rating change | Target | Implied |
|---|---|---|---|---|---|
| Oct 14, 2026 | Initiated | Citigroup | Buy | $46 | +210.4% |
| Oct 13, 2026 | Initiated | Citizens | Mkt Outperform | $35 | +136.2% |
| Jun 10, 2026 | Initiated | B. Riley Securities | Buy | $45 | +203.6% |
| Apr 24, 2026 | Initiated | Deutsche Bank | Buy | $40 | +169.9% |
| Mar 12, 2026 | Resumed | BTIG Research | Buy | $48 | +223.9% |
| Jan 13, 2026 | Initiated | Rodman & Renshaw | Buy | $48 | +223.9% |
| Dec 04, 2025 | Initiated | Oppenheimer | Outperform | $45 | +203.6% |
| Nov 24, 2025 | Initiated | Truist | Buy | ||
| Nov 10, 2025 | Initiated | BTIG Research | Buy | $50 | +237.4% |
| Nov 05, 2025 | Initiated | Piper Sandler | Overweight | $48 | +223.9% |
Peers
Mkt cap| Ticker | Company | Mkt cap |
|---|---|---|
| ELVN | Enliven Therapeutics Inc | 3.56B |
| ONC | BeOne Medicines Ltd ADR | 43.79B |
| ZLAB | Zai Lab Limited ADR | 2.94B |
| ABBV | Abbvie Inc | 521.45B |
| NVS | Novartis AG ADR | 293.05B |
| RIGL | Rigel Pharmaceuticals | 860.34M |
| LEGN | Legend Biotech Corp ADR | 3.60B |
| TAK | Takeda Pharmaceutical Co ADR | 68.57B |
| HCM | HUTCHMED (China) Limited ADR | 2.59B |
| LLY | Lilly(Eli) & Co | 1346.49B |
Insider trading
4 filings| Insider | Relationship | Date | Transaction | Cost | Shares | Value | Total held | Form |
|---|---|---|---|---|---|---|---|---|
| Zhai Yifan | Chief Medical Officer | May 21 '26 | Option Exercise | 0.00 | 95,575 | 0 | 1,193,569 | May 22 04:44 PM |
| Zhai Yifan | Chief Medical Officer | May 21 '26 | Option Exercise | 0.00 | 92,746 | 0 | 405,280 | May 22 04:44 PM |
| Yang Dajun | Chairman and CEO | May 21 '26 | Option Exercise | 0.00 | 92,746 | 0 | 405,280 | May 22 04:18 PM |
| Yang Dajun | Chairman and CEO | May 21 '26 | Option Exercise | 0.00 | 95,575 | 0 | 1,193,569 | May 22 04:18 PM |
News
latest 14 of 166- Ascentage Pharma to Present Data from Multiple Trials, Including an Oral Presentation of APG-5918 at ASH 2026 (GlobeNewswire) +11.80%
- Ascentage Pharma to Participate in Two Upcoming Investor Conferences in London (GlobeNewswire)
- Ascentage Pharma's Lisaftoclax Granted Breakthrough Therapy Designation in China for Treatment-Naive CLL/SLL (GlobeNewswire)
- Ascentage Pharma to Participate in Four Upcoming Investor Conferences (GlobeNewswire)
- Ascentage Pharma Reports 2026 Interim Unaudited Financial Results and Provides Business Updates (GlobeNewswire)
- Ascentage Pharma to Participate in the Evercore 2nd Annual China Biotech Summit (GlobeNewswire)
- CORRECTION: Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026 (GlobeNewswire)
- Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026 (GlobeNewswire)
- Ascentage Pharma Appoints Dr. Faical Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer (GlobeNewswire)
- Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026 (GlobeNewswire)
- Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress (GlobeNewswire)
- Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026 (GlobeNewswire)
- Ascentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026 (GlobeNewswire)
- Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026 (GlobeNewswire)
Quarterly earnings
2026S1 EPS -1.300 missed -0.220. Sales 44.85 missed 53.63
The outline behind the bar is the estimate. The filled bar is the print. Green beat it, red missed it.
| Period | Reported | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | Surprise | Year-ago quarter | Analysts | Next session |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026S1ended 2026-06-30 | 2026-08-18 16:30 | -1.300 | -0.220 | -0.325 | 44.85 | 53.63 | EPS +491.0% · sales -16.4% | - | 1 | Open -0.30% vs SPY +0.38%. Close -0.93% vs SPY +0.21% |
| 2025S2ended 2025-12-31 | 2026-03-24 16:30 | -0.650 | -0.830 | -0.988 | 49.49 | 44.40 | EPS -21.7% · sales +11.5% | - | 1 | Open +3.05% vs SPY +0.84%. Close +0.27% vs SPY +0.56% |
| 2025S1ended 2025-06-30 | 2025-08-20 16:30 | -0.964 | - | -0.954 | 32.56 | - | EPS - · sales - | - | - | Open -2.37% vs SPY -0.29%. Close +1.05% vs SPY -0.40% |
| 2024S1ended 2024-06-30 | 2024-08-22 16:30 | 0.308 | - | 0.305 | 115.41 | - | EPS - · sales - | - | - | - |
| 2026S2ended 2026-12-31 | - | - | -0.300 | - | - | 49.77 | EPS - · sales - | - | 6 EPS · 5 sales | - |
| 2027S1ended 2027-06-30 | - | - | -0.287 | - | - | 60.07 | EPS - · sales - | - | 3 | - |
| 2027S2ended 2027-12-31 | - | - | -0.297 | - | - | 64.87 | EPS - · sales - | - | 3 | - |
Annual earnings
2025FY EPS -2.024 missed -1.278, from -0.738 a year earlier. Sales 83.24 beat 75.65, from 135.01 a year earlier
Reported years only. The outline behind the bar is the estimate. A later year with no print stays in the table.
earnings feed, not the snapshot. Not the statement ratio.
| Period | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | P/E, earnings feed |
|---|---|---|---|---|---|---|
| 2030FYestimate | - | 1.251 | - | - | 1,119 | 11.85 |
| 2029FYestimate | - | 0.492 | - | - | 725.55 | 30.13 |
| 2028FYestimate | - | -0.275 | - | - | 385.72 | - |
| 2027FYestimate | - | -0.464 | - | - | 251.04 | - |
| 2026FYestimate | - | -0.501 | - | - | 114.39 | - |
| 2025FY | -2.024 | -1.278 | -0.997 | 83.24 | 75.65 | - |
| 2024FY | -0.738 | -0.258 | -0.746 | 135.01 | 153.68 | - |
Estimate revisions
Latest snapshot of each period and type. 2026FY R -1.19 per share.
| Period | Type | Scale | Date | Mean | vs prior date |
|---|---|---|---|---|---|
| 2026FY | S | - | 2026-11-11 | 114.39 | +0.0% |
| 2026FY | R | per share | 2026-11-09 | -1.19 | 0.0% |
| 2026FY | E | per share | 2026-11-03 | -0.50 | +0.1% |
| 2026S2 | E | per share | 2026-11-02 | -0.30 | 0.0% |
| 2026S2 | R | per share | 2026-11-02 | -0.34 | 0.0% |
| 2026S2 | S | per share | 2026-10-16 | 49.77 | 0.0% |
| 2026S1 | E | per share | 2026-07-30 | -0.22 | -13.7% |
| 2026S1 | R | per share | 2026-07-30 | -0.22 | -13.7% |
| 2026S1 | S | per share | 2026-07-30 | 53.63 | +11.6% |
| 2025FY | E | per share | 2026-03-22 | -1.28 | -7.4% |
| 2025FY | S | per share | 2026-03-22 | 75.65 | -0.4% |
| 2025S2 | E | per share | 2026-03-20 | -0.83 | +58.1% |
| 2025FY | R | per share | 2026-03-20 | -0.86 | +19.4% |
| 2025S2 | S | per share | 2026-03-20 | 44.40 | +13.0% |
| 2025S2 | R | per share | 2025-11-04 | -0.22 | - |
| 2024S2 | E | per share | 2025-03-26 | 0.02 | - |
Estimate history
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -0.356 | -1.061 | -7.343 | -1.819 | -1.906 | -1.989 | -1.851 | -0.746 | -1.942 |
| Sales USD millions | 1 | 1 | 2 | 2 | 4 | 31 | 31 | 136 | 80 |
| Shares million shares | 52 | 52 | 52 | 57 | 65 | 66 | 72 | 78 | 93 |
Income statement, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 91.82 | 79.87-41.4% | 136.26+334.9% | 31.33+0.6% | 31.14+619.2% | 4.33+140.6% | 1.80-14.3% | 2.10+103.9% | 1.03 |
| Cost of Goods Sold Incl. D&A | 15.45 | 16.67+5.4% | 15.82+3.9% | 15.22+22.7% | 12.40+152.5% | 4.91+15.3% | 4.26+3.1% | 4.13+48.0% | 2.79 |
| Gross Profit | 76.37 | 63.20-47.5% | 120.44+647.6% | 16.11-14.1% | 18.75 | -0.58 | -2.45 | -2.03 | -1.76 |
| Selling, General and Administrative Excl. Other | 278.36 | 231.83+34.0% | 173.07+21.9% | 142.01-5.3% | 149.94+4.0% | 144.11+49.0% | 96.71+11.5% | 86.70+78.8% | 48.48 |
| Research and Development | 184.02 | 154.91+22.0% | 126.97+33.5% | 95.11-11.4% | 107.29-8.0% | 116.58+46.6% | 79.52+22.2% | 65.05+81.5% | 35.84 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -201.99 | -168.63 | -52.63 | -125.90 | -131.19 | -144.69 | -99.16 | -88.73 | -50.25 |
| Interest Expense | 7.59 | 7.52-16.1% | 8.96-33.9% | 13.56+73.0% | 7.84+202.7% | 2.59+184.6% | 0.91+46.8% | 0.62-88.9% | 5.58 |
| Unusual Expense | 11.47 | 3.80 | -0.04 | -0.30 | -1.41 | -5.71-236.0% | 4.20-96.9% | 137.42+7983.5% | 1.70 |
| Net Income Before Taxes | -208.43 | -171.99 | -54.88 | -131.82 | -131.71 | -129.04 | -97.86 | -214.52 | -52.43 |
| Income Taxes | 2.19 | 0.97-33.1% | 1.45 | -1.01 | -0.63 | -7.73-2593.5% | 0.31 | -0.23 | -0.24 |
| Consolidated Net Income | -210.58 | -172.91 | -56.37 | -130.66 | -131.12 | -121.32 | -98.17 | -214.29 | -52.18 |
| Net Income From Continuing Operations | -210.51 | -172.88 | -56.34 | -130.65 | -131.12 | -121.32 | -98.17 | -214.29 | -52.18 |
| Net Income | -210.51 | -172.88 | -56.34 | -130.65 | -131.12 | -121.32 | -98.17 | -214.29 | -52.18 |
| EPS (Recurring) per share | -2.17 | -1.91 | -0.75 | -1.85 | -2.00 | -1.97 | -1.76 | -4.05 | -1.04 |
| EPS (Basic, Before Extraordinaries) per share | -2.26 | -1.94 | -0.75 | -1.85 | -1.99 | -1.91 | -1.82 | -7.34 | -1.06 |
| EPS (Diluted) per share | -2.26 | -1.94 | -0.75 | -1.85 | -1.99 | -1.91 | -1.82 | -7.34 | -1.06 |
| EBITDA | -189.68 | -156.60 | -39.69 | -114.99 | -122.06 | -140.30 | -95.19 | -84.90 | -47.46 |
| Non-Operating Income (Expense) | 12.63 | 7.96+19.5% | 6.66-9.3% | 7.34+24.0% | 5.92-52.8% | 12.53+95.8% | 6.40-47.7% | 12.24+140.0% | 5.10 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 4.24 | 2.18+0.9% | 2.16-34.5% | 3.30+41.6% | 2.33-57.3% | 5.46-29.5% | 7.74+4.6% | 7.40+149.2% | 2.97 |
| Price To Sales Ratio ratio | 17.85 | 29.25 | - | - | - | - | - | - | - |
| Gross Margin % | 83.18 | 79.13 | 88.39 | 51.41 | 60.20 | -13.41 | -136.05 | -96.58 | -171.22 |
| Operating Margin % | -220.00 | -211.14 | -38.63 | -401.83 | -421.25 | -3,343.50 | -5,497.42 | -4,224.55 | -4,884.31 |
| Net Margin % | -229.27 | -216.47 | -41.34 | -416.98 | -421.02 | -2,803.38 | -5,442.62 | -10,202.67 | -5,072.82 |
| Shares Outstanding million shares | 92.94 | 92.94+18.5% | 78.44+8.8% | 72.11+9.5% | 65.86+0.8% | 65.36+15.7% | 56.51+8.2% | 52.230.0% | 52.23 |
| Market Capitalization | 1,401.27 | 1,401.27-42.1% | 2,418.71 | - | - | - | - | - | - |
Income statement, quarterly
| Metric | 2026S16/30/2026 | 2025S212/31/2025 | 2025S16/30/2025 | 2024S212/31/2024 | 2024S16/30/2024 | 2023S212/31/2023 | 2023S16/30/2023 | 2022S212/31/2022 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 44.03 | 47.78 | 32.21 | 21.86 | 114.16 | 10.95 | 20.59 | 16.32 |
| Cost of Goods Sold Incl. D&A | 7.07 | 8.37 | 8.29 | 7.78 | 8.04 | 7.29 | 7.94 | 6.79 |
| Gross Profit | 36.96 | 39.41 | 23.92 | 14.07 | 106.12 | 3.66 | 12.64 | 9.53 |
| Selling, General and Administrative Excl. Other | 146.56 | 131.80 | 100.28 | 93.03 | 80.07 | 77.17 | 64.57 | 78.16 |
| Research and Development | 100.00 | 84.02 | 70.99 | 67.85 | 59.15 | 54.87 | 44.70 | 57.54 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -109.60 | -92.39 | -76.36 | -78.96 | 26.05 | -73.51 | -51.93 | -68.63 |
| Interest Expense | 3.91 | 3.69 | 3.83 | 4.23 | 4.72 | 5.99 | 7.61 | 4.83 |
| Unusual Expense | 3.45 | 8.02 | -4.11 | 0.03 | -0.07 | 0.07 | -0.38 | 0.01 |
| Net Income Before Taxes | -117.05 | -91.39 | -80.68 | -77.89 | 22.75 | -73.80 | -57.68 | -69.43 |
| Income Taxes | 1.99 | 0.20 | 0.76 | 1.44 | 0.01 | -1.37 | 0.40 | -1.25 |
| Consolidated Net Income | -119.03 | -91.54 | -81.44 | -79.20 | 22.57 | -72.31 | -58.05 | -68.22 |
| Net Income From Continuing Operations | -118.99 | -91.52 | -81.43 | -79.19 | 22.59 | -72.30 | -58.05 | -68.22 |
| Net Income | -118.99 | -91.52 | -81.43 | -79.19 | 22.59 | -72.30 | -58.05 | -68.22 |
| EPS (Recurring) per share | -1.25 | -0.93 | -0.99 | -1.06 | 0.30 | -1.00 | -0.85 | -1.04 |
| EPS (Basic, Before Extraordinaries) per share | -1.28 | -0.99 | -0.95 | -1.06 | 0.31 | -1.00 | -0.85 | -1.04 |
| EPS (Diluted) per share | -1.28 | -0.99 | -0.95 | -1.06 | 0.31 | -1.00 | -0.85 | -1.04 |
| EBITDA | -103.28 | -86.40 | -70.33 | -72.57 | 32.61 | -67.93 | -46.60 | -64.27 |
| Non-Operating Income (Expense) | -0.09 | 12.71 | -4.60 | 5.33 | 1.35 | 5.78 | 1.47 | 4.03 |
| Stock Option Compensation Expense | 3.41 | 0.82 | 1.35 | 1.27 | 0.91 | 1.34 | 1.97 | 1.65 |
| Price To Sales Ratio ratio | 17.85 | 30.38 | 62.19 | - | - | - | - | - |
| Gross Margin % | 83.94 | 82.48 | 74.26 | 64.39 | 92.96 | 33.42 | 61.41 | 58.40 |
| Operating Margin % | -248.91 | -193.35 | -237.05 | -361.23 | 22.82 | -671.10 | -252.22 | -420.42 |
| Net Margin % | -270.24 | -191.53 | -252.79 | -362.28 | 19.79 | -660.02 | -281.95 | -417.90 |
| Shares Outstanding million shares | 92.94 | 92.94 | 86.70 | 78.44 | 78.23 | 72.11 | 72.14 | 65.86 |
| Market Capitalization | 1,401.27 | 2,434.48 | 3,415.78 | 3,435.30 | - | - | - | - |
Balance sheet, annual
| Metric | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 | 2017FY12/31/2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 353.47+104.6% | 172.79+12.0% | 154.23-28.2% | 214.66-21.5% | 273.61+74.7% | 156.64+23.6% | 126.69-10.5% | 141.50+130.9% | 61.27 |
| Short Term Receivables | 43.09+217.5% | 13.57-41.2% | 23.06+160.6% | 8.85-26.3% | 12.00+488.2% | 2.04+466.7% | 0.36-53.2% | 0.77-36.4% | 1.21 |
| Inventories | 4.10+355.6% | 0.90-60.5% | 2.28+67.6% | 1.36+119.4% | 0.62 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 20.65+40.5% | 14.70+47.6% | 9.96-5.6% | 10.55+10.1% | 9.58+51.8% | 6.31+82.4% | 3.46+76.5% | 1.96+55.6% | 1.26 |
| Total Current Assets | 421.31+108.6% | 201.96+6.6% | 189.53-19.5% | 235.41-20.4% | 295.81+79.3% | 165.00+26.4% | 130.51-9.5% | 144.23+126.3% | 63.73 |
| Net Property, Plant & Equipment | 118.66-4.4% | 124.10-8.1% | 134.97+44.3% | 93.51-30.2% | 134.04+83.1% | 73.22+258.4% | 20.43+108.7% | 9.79+214.8% | 3.11 |
| Total Investments and Advances | 5.30+14.2% | 4.64+73.8% | 2.67-95.0% | 53.79+1130.9% | 4.37-10.1% | 4.86+5.2% | 4.62-46.7% | 8.67+86.1% | 4.66 |
| Long-Term Note Receivable | - | - | - | - | - | - | - | - | 0.90 |
| Intangible Assets | 12.97-5.9% | 13.79-11.2% | 15.53-1.0% | 15.68+17.5% | 13.35-4.2% | 13.93+0.1% | 13.91-4.5% | 14.56-10.1% | 16.19 |
| Deferred Tax Assets | 6.41-8.2% | 6.98-17.3% | 8.44+8.1% | 7.81-3.6% | 8.10 | - | - | - | - |
| Other Assets | 4.37-45.9% | 8.08+469.0% | 1.42+51.1% | 0.94-83.3% | 5.63-26.7% | 7.68+118.2% | 3.52+94.5% | 1.81 | 0.00 |
| Total Assets | 569.02+58.3% | 359.56+2.0% | 352.56-13.4% | 407.13-11.7% | 461.31+74.3% | 264.69+53.0% | 173.00-3.4% | 179.06+102.1% | 88.59 |
| Short Term Debt Incl. Current Port. of LT Debt | 176.13+59.0% | 110.75+27.4% | 86.91+16.5% | 74.57+861.0% | 7.76-16.3% | 9.27-30.0% | 13.24+142.0% | 5.47 | 0.00 |
| Accounts Payable | 15.27+21.2% | 12.60+23.4% | 10.21-25.7% | 13.75+23.7% | 11.12+211.5% | 3.57+89.9% | 1.88+154.1% | 0.74+25.4% | 0.59 |
| Income Tax Payable | - | - | - | - | 0.00-100.0% | 0.54 | - | - | - |
| Other Current Liabilities | 43.76+20.0% | 36.47+5.4% | 34.59-10.0% | 38.44+1.7% | 37.78+31.0% | 28.84+107.6% | 13.89+52.3% | 9.12-19.4% | 11.32 |
| Total Current Liabilities | 235.17+47.1% | 159.83+21.3% | 131.72+3.9% | 126.75+123.7% | 56.66+34.2% | 42.23+45.6% | 29.01+89.2% | 15.33+28.8% | 11.90 |
| Long Term Debt | 108.36-11.1% | 121.85-26.7% | 166.27-9.3% | 183.31+12.9% | 162.37+121.6% | 73.26+5450.0% | 1.32-99.6% | 302.97 | 0.00 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax Liabilities | 1.83+10.2% | 1.66+11.4% | 1.49-14.9% | 1.75-19.0% | 2.16-8.1% | 2.35-3.3% | 2.43-10.0% | 2.70-12.9% | 3.10 |
| Other Liabilities | 31.80-8.9% | 34.90-8.2% | 38.00+20.6% | 31.50-22.9% | 40.85+263.1% | 11.25+52.9% | 7.36+397.3% | 1.48-98.4% | 91.72 |
| Total Liabilities | 377.16+18.5% | 318.23-5.7% | 337.47-1.7% | 343.31+31.0% | 262.03+103.0% | 129.09+221.7% | 40.13-87.6% | 322.48+202.2% | 106.72 |
| Non-Equity Reserves | 0.93-75.3% | 3.77-26.5% | 5.13+2.0% | 5.03-9.2% | 5.54-9.9% | 6.15+22.3% | 5.03+28.3% | 3.92+87.6% | 2.09 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 189.53+423.7% | 36.19+324.8% | 8.52-85.5% | 58.79-69.7% | 193.73+49.6% | 129.46+1.3% | 127.84 | -147.34 | -20.22 |
| Total Shareholders Equity | 189.53+423.7% | 36.19+324.8% | 8.52-85.5% | 58.79-69.7% | 193.73+49.6% | 129.46+1.3% | 127.84 | -147.34 | -20.22 |
| Accumulated Minority Interest | 1.40+2.2% | 1.37-4.9% | 1.44 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 190.92+408.3% | 37.56+277.1% | 9.96-83.1% | 58.79-69.7% | 193.73+49.6% | 129.46+1.3% | 127.84 | -147.34 | -20.22 |
| Total Liabilities & Stockholders Equity | 569.02+58.3% | 359.56+2.0% | 352.56-13.4% | 407.13-11.7% | 461.31+74.3% | 264.69+53.0% | 173.00-3.4% | 179.06+102.1% | 88.59 |
| Book Value Per Share per share | 2.04+343.5% | 0.46+283.3% | 0.12-86.5% | 0.89-69.9% | 2.96+29.3% | 2.29-6.5% | 2.45 | -2.82 | -0.39 |
| Tangible Book Value Per Share per share | 1.90+555.2% | 0.29 | -0.10-115.4% | 0.65-76.4% | 2.76+35.3% | 2.04-6.4% | 2.18 | -3.10 | -0.70 |
| Full-Time Employees people | 767+35.3% | 567-2.7% | 583+0.5% | 580-5.4% | 613+41.6% | 433+5.6% | 410+35.3% | 303 | - |
| Price to Book Ratio ratio | 17.02 | 24.32 | - | - | - | - | - | - | - |
| Return on Assets % | -37.24 | -15.82 | -34.39 | -30.20 | -33.42 | -44.86 | -122.08 | -39.00 | -20.16 |
| Return on Equity % | -153.18 | -251.98 | -388.23 | -103.85 | -75.08 | -76.31 | - | - | - |
| Return on Invested Capital % | -58.04 | -35.64 | -74.75 | -54.16 | -34.07 | -48.43 | -165.91 | -33.53 | - |
| Quick Ratio ratio | 1.77 | 1.26 | 1.42 | 1.85 | 5.21 | 3.91 | 4.50 | 9.41 | 5.35 |
| Current Ratio ratio | 1.79 | 1.26 | 1.44 | 1.86 | 5.22 | 3.91 | 4.50 | 9.41 | 5.35 |
Cash flow, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | - | -171.95 | -54.92 | -131.67 | -131.75 | -129.04 | -97.86 | -214.52 | -52.43 |
| Depreciation | - | 12.03-7.1% | 12.95+18.7% | 10.91+19.5% | 9.13+108.0% | 4.39+10.6% | 3.97+3.7% | 3.83+37.3% | 2.79 |
| Other Funds (Non Cash) | -15.81 | 9.41+252.4% | 2.67-59.1% | 6.53+151.2% | 2.60 | -1.12-109.7% | 11.57-91.8% | 141.85+1418.7% | 9.34 |
| Funds from Operations | -177.17 | -150.51 | -39.31 | -114.22 | -120.02 | -125.77 | -82.32 | -68.85 | -40.30 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | - | -22.60-246.5% | 15.43 | -0.17-101.4% | 12.49-65.4% | 36.05 | -5.71-267.9% | 3.40-16.9% | 4.09 |
| Cash from Operating Activities | -199.98 | -173.11 | -23.87 | -114.39 | -107.53 | -89.72 | -88.02 | -65.45 | -36.20 |
| Capital Expenditures | -2.84 | -3.84 | -3.37 | -8.02 | -35.19 | -67.70 | -36.43 | -11.78 | -7.47 |
| Net Assets From Acquisitions | -0.11 | -6.03 | -1.32 | -2.82 | -2.97 | -3.10 | 0.00 | 0.00 | -5.04 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00-100.0% | 1.45+314.3% | 0.35+600.0% | 0.05 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | 95.25 | -129.25 | -45.61-427.2% | 13.94 | -19.31 | -1.59-107.6% | 20.88 | -17.35-130.6% | 56.77 |
| Purchase of Investments | -42.48 | -129.25 | -45.61 | 0.00 | -19.31 | -279.10 | -314.41 | -281.64 | -76.73 |
| Sale Or Maturity of Investments | 137.73 | 0.00 | 0.00-100.0% | 13.94 | 0.00-100.0% | 277.51-17.2% | 335.29+26.9% | 264.29+98.0% | 133.50 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | 92.30 | -139.12 | -50.30-1205.5% | 4.55 | -57.12 | -72.34 | -15.56 | -29.14-165.9% | 44.25 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 191.42 | 319.38+330.5% | 74.19+13.2% | 65.51 | -3.97-102.0% | 195.17+117.0% | 89.94+53.7% | 58.51-53.4% | 125.49 |
| Repurchase of Common Pref Stock | -1.14 | -1.26 | 0.00 | -0.84 | -3.98 | -4.01 | 0.00 | 0.00 | -11.42 |
| Sale of Common Pref Stock | 192.56 | 320.64+332.2% | 74.19+11.8% | 66.35 | 0.00-100.0% | 199.18+121.5% | 89.94+53.7% | 58.51-57.3% | 136.92 |
| Proceedsfrom Stock Options | 192.56 | 320.64+332.2% | 74.19+11.8% | 66.35 | 0.00-100.0% | 183.07+103.5% | 89.94+53.7% | 58.51-57.3% | 136.92 |
| Issuance or Reduction of Debt, Net | 60.84 | 44.10 | -19.03 | -0.37-100.4% | 105.31+23.8% | 85.06+35.6% | 62.71+766.2% | 7.24+36.9% | 5.29 |
| Change in Long Term Debt | - | - | - | 0.00 | 0.00 | - | - | 0.00 | 0.00 |
| Issuance of Long Term Debt | - | - | - | 0.00 | 0.00 | - | - | 0.00 | 0.00 |
| Reduction of Long Term Debt | - | - | - | 0.00 | 0.00 | - | - | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | -0.21 | -1.63 | -1.85 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | -0.21 | -1.63 | -1.85 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | 243.62 | 360.50+591.3% | 52.15-18.0% | 63.63-36.0% | 99.37-64.4% | 278.82+84.0% | 151.54+134.4% | 64.64-50.4% | 130.28 |
| Exchange Rate Effect | -15.89 | -8.80-563.2% | 1.90-51.7% | 3.93-54.4% | 8.62 | -3.61 | -6.04-3652.9% | 0.17-95.8% | 4.07 |
| Net Change in Cash | 120.06 | 39.47 | -20.13 | -42.29 | -56.67-150.1% | 113.15+169.9% | 41.92 | -29.78-120.9% | 142.40 |
| Free Cash Flow | -202.81 | -176.94 | -27.25 | -120.90 | -137.72 | -157.24 | -124.23 | -76.66 | -43.48 |
| Preferred Dividends (Cash Flow) | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Taxes & Investment Tax Credit | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Balance sheet, quarterly
| Metric | 2026S16/30/2026 | 2025S212/31/2025 | 2025S16/30/2025 | 2024S212/31/2024 | 2024S16/30/2024 | 2023S212/31/2023 | 2023S16/30/2023 | 2022S212/31/2022 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 279.36 | 353.47 | 231.87 | 172.79 | 151.43 | 154.23 | 217.73 | 214.66 |
| Short Term Receivables | 23.05 | 43.09 | 10.94 | 13.57 | 102.33 | 23.06 | 11.24 | 8.85 |
| Inventories | 9.48 | 4.10 | 1.20 | 0.90 | 1.48 | 2.28 | 0.69 | 1.36 |
| Other Current Assets | 26.08 | 20.65 | 22.37 | 14.70 | 15.04 | 9.96 | 12.75 | 10.55 |
| Total Current Assets | 337.97 | 421.31 | 266.38 | 201.96 | 270.28 | 189.53 | 242.40 | 235.41 |
| Net Property, Plant & Equipment | 117.96 | 118.66 | 121.69 | 124.10 | 128.16 | 134.97 | 87.15 | 93.51 |
| Total Investments and Advances | 5.90 | 5.30 | 5.21 | 4.64 | 4.57 | 2.67 | 50.31 | 53.79 |
| Intangible Assets | 9.18 | 12.97 | 13.35 | 13.79 | 14.38 | 15.53 | 14.43 | 15.68 |
| Deferred Tax Assets | 2.71 | 6.41 | 4.66 | 6.98 | 7.58 | 8.44 | 6.99 | 7.81 |
| Other Assets | 3.88 | 4.37 | 13.82 | 8.08 | 2.66 | 1.42 | 0.44 | 0.94 |
| Total Assets | 477.60 | 569.02 | 425.11 | 359.56 | 427.61 | 352.56 | 401.72 | 407.13 |
| Short Term Debt Incl. Current Port. of LT Debt | 217.40 | 176.13 | 116.36 | 110.75 | 100.40 | 86.91 | 55.80 | 74.57 |
| Accounts Payable | 15.76 | 15.27 | 16.56 | 12.60 | 11.43 | 10.21 | 6.57 | 13.75 |
| Other Current Liabilities | 44.43 | 43.76 | 40.03 | 36.47 | 34.78 | 34.59 | 26.14 | 38.44 |
| Total Current Liabilities | 277.58 | 235.17 | 172.95 | 159.83 | 146.62 | 131.72 | 88.50 | 126.75 |
| Long Term Debt | 91.29 | 108.36 | 123.14 | 121.85 | 133.57 | 166.27 | 174.95 | 183.31 |
| Deferred Tax Liabilities | - | 1.83 | - | 1.66 | 0.80 | 1.49 | 1.56 | 1.75 |
| Other Liabilities | 25.34 | 31.80 | 34.69 | 34.90 | 39.76 | 38.00 | 54.08 | 31.50 |
| Total Liabilities | 394.21 | 377.16 | 330.78 | 318.23 | 320.76 | 337.47 | 319.09 | 343.31 |
| Non-Equity Reserves | 0.00 | 0.93 | 0.00 | 3.77 | 0.00 | 5.13 | 0.00 | 5.03 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 82.00 | 189.53 | 92.94 | 36.19 | 105.48 | 8.52 | 81.21 | 58.79 |
| Total Shareholders Equity | 82.00 | 189.53 | 92.94 | 36.19 | 105.48 | 8.52 | 81.21 | 58.79 |
| Accumulated Minority Interest | 1.39 | 1.40 | 1.38 | 1.37 | 1.38 | 1.44 | 1.42 | 0.00 |
| Total Equity | 83.39 | 190.92 | 94.33 | 37.56 | 106.86 | 9.96 | 82.62 | 58.79 |
| Total Liabilities & Stockholders Equity | 477.60 | 569.02 | 425.11 | 359.56 | 427.61 | 352.56 | 401.72 | 407.13 |
| Book Value Per Share per share | 0.88 | 2.04 | 1.07 | 0.46 | 1.35 | 0.12 | 1.13 | 0.89 |
| Tangible Book Value Per Share per share | 0.78 | 1.90 | 0.92 | 0.29 | 1.16 | -0.10 | 0.93 | 0.65 |
| Price to Book Ratio ratio | 17.02 | 24.48 | 85.33 | 85.82 | - | - | - | - |
| Return on Assets % | -46.64 | -37.25 | -37.67 | -15.90 | -11.99 | -34.32 | -29.53 | -30.16 |
| Return on Equity % | -240.66 | -153.24 | -161.90 | -253.16 | -53.25 | -387.34 | -119.01 | -103.74 |
| Return on Invested Capital % | -68.67 | -30.72 | -37.68 | -50.10 | 9.45 | -41.36 | -22.66 | -28.18 |
| Quick Ratio ratio | 1.18 | 1.77 | 1.53 | 1.26 | 1.83 | 1.42 | 2.73 | 1.85 |
| Current Ratio ratio | 1.22 | 1.79 | 1.54 | 1.26 | 1.84 | 1.44 | 2.74 | 1.86 |
Cash flow, quarterly
| Metric | 2026S16/30/2026 | 2025S212/31/2025 | 2025S16/30/2025 | 2024S212/31/2024 | 2024S16/30/2024 | 2023S212/31/2023 | 2023S16/30/2023 | 2022S212/31/2022 |
|---|---|---|---|---|---|---|---|---|
| Other Funds (Non Cash) | -88.48 | 72.67 | -63.17 | 56.38 | -53.71 | 67.40 | -61.01 | 57.23 |
| Funds from Operations | -88.48 | -88.69 | -63.17 | 14.30 | -53.71 | -50.80 | -61.01 | -61.05 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | - | - | 0.00 | 0.00 | 0.00 |
| Cash from Operating Activities | -88.48 | -111.50 | -63.17 | 29.77 | -53.71 | -50.97 | -61.01 | -49.01 |
| Capital Expenditures | -1.73 | -1.11 | -2.76 | -1.09 | -2.29 | -2.84 | -5.02 | -11.58 |
| Net Assets From Acquisitions | 0.00 | -0.11 | -5.97 | -1.33 | 0.00 | -2.76 | 0.00 | -2.87 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.06 | 1.49 | -0.03 |
| Purchase or Sale of Investments | 137.29 | -42.04 | -88.38 | -29.82 | -15.90 | 17.97 | -4.33 | -18.62 |
| Purchase of Investments | -0.44 | -42.04 | -88.38 | -29.82 | -15.90 | 4.33 | -4.33 | -18.62 |
| Sale Or Maturity of Investments | 137.73 | 0.00 | 0.00 | 0.00 | 0.00 | 13.64 | 0.00 | 0.00 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | 135.56 | -43.26 | -97.11 | -32.24 | -18.19 | 12.31 | -7.86 | -33.09 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | -1.14 | 192.56 | 129.71 | 0.66 | 73.73 | -3.69 | 67.82 | -3.83 |
| Repurchase of Common Pref Stock | -1.14 | 0.00 | -1.27 | 0.27 | -0.27 | -0.82 | 0.00 | -3.84 |
| Sale of Common Pref Stock | 0.00 | 192.56 | 130.98 | 0.39 | 74.00 | -2.88 | 67.82 | 0.00 |
| Proceedsfrom Stock Options | 0.00 | 192.56 | 130.97 | 0.39 | 74.00 | -2.88 | 67.82 | 0.00 |
| Issuance or Reduction of Debt, Net | 16.34 | 37.56 | 6.94 | -6.09 | -12.98 | 16.35 | -16.71 | 28.50 |
| Change in Long Term Debt | - | - | - | - | - | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | - | - | - | - | - | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | - | - | - | - | - | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | 0.00 | -0.21 | -1.44 | -1.43 | -0.43 | -21.64 | 21.64 | 0.00 |
| Other Financing Activities Uses | 0.00 | -0.21 | -1.44 | -1.43 | -0.43 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | 14.53 | 229.09 | 134.66 | -7.32 | 59.60 | -9.82 | 72.10 | 23.76 |
| Exchange Rate Effect | -7.51 | -8.38 | -0.50 | 1.47 | 0.44 | 0.67 | 3.17 | 6.18 |
| Net Change in Cash | 54.11 | 65.95 | -26.12 | -8.31 | -11.86 | -47.80 | 6.40 | -52.16 |
| Free Cash Flow | -90.21 | -112.61 | -65.93 | 28.68 | -56.00 | -52.44 | -65.91 | -60.93 |
Revenue breakdown
USD millions, so a column adds up to the income statement. Share is of the latest year in that split. The change is versus the older year shown, not TTM.
| Name | 2024 | 2025 | vs 2024 | 2025 share |
|---|---|---|---|---|
| Others | - | 10.41 | - | 13.0% |
| Products | - | 69.47 | - | 87.0% |
| Types Of Goods Or Services | 136.45 | - | - | - |
| Total | 136.45 | 79.89 | -41.5% | 100.0% |
| Name | 2024 | 2025 | vs 2024 | 2025 share |
|---|---|---|---|---|
| Chinese Mainland | 42.06 | 79.89 | +90.0% | 100.0% |
| Switzerland | 94.40 | - | - | - |
| Total | 136.45 | 79.89 | -41.5% | 100.0% |
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | - | 0.0M | - | 7.16K |
| 2026-10-15 | - | 0.0M | - | 6.43K |
| 2026-09-30 | - | 0.0M | - | 6.72K |
| 2026-09-15 | - | 0.0M | - | 10.63K |
| 2026-08-31 | - | 0.0M | - | 11.01K |
| 2026-08-14 | - | 0.0M | - | 11.73K |
| 2026-07-31 | - | 0.0M | - | 11.40K |
| 2026-07-15 | - | 0.0M | - | 11.32K |
| 2026-06-30 | - | 0.2M | - | 10.18K |
| 2026-06-15 | - | 0.0M | - | 6.08K |
| 2026-05-29 | - | 0.0M | - | 5.02K |
| 2026-05-15 | - | 0.0M | - | 3.80K |
| 2026-04-30 | - | 0.0M | - | 3.05K |
| 2026-04-15 | - | 0.0M | - | 3.18K |
| 2026-03-31 | - | 0.0M | - | 3.33K |
| 2026-03-13 | - | 0.0M | - | 3.34K |
| 2026-02-27 | - | 0.0M | - | 3.43K |
| 2026-02-13 | - | 0.0M | - | 3.89K |
| 2026-01-30 | - | 0.0M | - | 4.89K |
| 2026-01-15 | - | 0.0M | - | 5.39K |
Option chain
expiry 2026-11-13| Type | Strike | Bid | Ask | Last | IV | Open int | Volume | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|
| No option chain for this symbol. | ||||||||||
Latest SEC filings
30| Filed | Form | Description | Period | Link |
|---|---|---|---|---|
| 2026-11-05 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-11-05 | SEC |
| 2026-10-28 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-10-28 | SEC |
| 2026-10-22 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-10-22 | SEC |
| 2026-10-21 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-10-21 | SEC |
| 2026-10-15 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-10-15 | SEC |
| 2026-09-29 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-09-28 | SEC |
| 2026-09-17 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-09-17 | SEC |
| 2026-08-20 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-08-20 | SEC |
| 2026-08-13 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-08-13 | SEC |
| 2026-08-05 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-08-05 | SEC |
| 2026-08-03 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-08-03 | SEC |
| 2026-07-27 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-07-27 | SEC |
| 2026-07-20 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-07-20 | SEC |
| 2026-07-20 | F-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers | SEC | |
| 2026-07-13 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-07-13 | SEC |
| 2026-06-30 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-06-30 | SEC |
| 2026-06-29 | 3 | Initial statement of beneficial ownership of securities | 2026-06-25 | SEC |
| 2026-06-15 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-06-15 | SEC |
| 2026-06-12 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-06-11 | SEC |
| 2026-06-10 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-06-10 | SEC |
| 2026-06-01 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-06-01 | SEC |
| 2026-05-28 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-05-28 | SEC |
| 2026-05-28 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-05-27 | SEC |
| 2026-05-22 | 4 | Statement of changes in beneficial ownership of securities | 2026-05-20 | SEC |
| 2026-05-22 | 4 | Statement of changes in beneficial ownership of securities | 2026-05-20 | SEC |
| 2026-05-22 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-05-22 | SEC |
| 2026-05-13 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-05-13 | SEC |
| 2026-05-12 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-05-12 | SEC |
| 2026-05-01 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-04-30 | SEC |
| 2026-04-29 | 20-F | Registration statement under Section 12 of the Securities Exchange Act of 1934 or an annual or transition report filed under Section 13(a) or 15(d) of the Exchange Act for a foreign private issuer. | 2025-12-31 | SEC |
Insider activity by month
| Month | Bought | Buys | Sold | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 0 | 0 |
| 2026-10 | 0 | 0 | 0 | 0 |
| 2026-09 | 0 | 0 | 0 | 0 |
| 2026-08 | 0 | 0 | 0 | 0 |
| 2026-07 | 0 | 0 | 0 | 0 |
| 2026-06 | 0 | 0 | 0 | 0 |
| 2026-05 | 0 | 0 | 0 | 0 |
| 2026-04 | 0 | 0 | 0 | 0 |
| 2026-03 | 0 | 0 | 0 | 0 |
| 2026-02 | 0 | 0 | 0 | 0 |
| 2026-01 | 0 | 0 | 0 | 0 |
| 2025-12 | 0 | 0 | 0 | 0 |
| 2025-11 | 0 | 0 | 0 | 0 |
Institutional holders
| Manager | % owned |
|---|---|
| Point72 Asset Management, L.P. | 0.01% |
| Arax Advisory Partners | 0.00% |
| MORGAN STANLEY | 0.00% |
| WELLS FARGO & COMPANY/MN | 0.00% |
| Nuveen, LLC | 0.00% |
| EverSource Wealth Advisors, LLC | 0.00% |
| UBS Group AG | 0.00% |
| ROYAL BANK OF CANADA | 0.00% |
| BlackRock, Inc. | 0.00% |
| NISA INVESTMENT ADVISORS, LLC | 0.00% |
Funds
| Fund | % owned |
|---|---|
| Fidelity Nasdaq Composite Index Fund | 0.00% |
OakChart. AAPG. Cached 15 minutes. Terms